{"id":"bevacizumab-plus-atezolizumab","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Hypertension"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"5-20%","effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL1201583","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Bevacizumab works by binding to VEGF-A, preventing its interaction with its receptor and subsequently inhibiting angiogenesis. Atezolizumab, on the other hand, binds to PD-L1, blocking its interaction with the programmed death-1 (PD-1) receptor on T cells, which enhances the anti-tumor immune response.","oneSentence":"Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), while atezolizumab is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1), thereby enhancing anti-tumor immune response.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:23:23.414Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, metastatic or recurrent"},{"name":"Renal cell carcinoma, metastatic"},{"name":"Urothelial carcinoma, locally advanced or metastatic"}]},"trialDetails":[{"nctId":"NCT02839707","phase":"PHASE2, PHASE3","title":"Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-06-23","conditions":"Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma","enrollment":444},{"nctId":"NCT04524871","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-11-01","conditions":"Advanced Liver Cancers","enrollment":518},{"nctId":"NCT05211323","phase":"PHASE2","title":"A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-12-07","conditions":"Combined Hepatocellular Carcinoma and Cholangiocarcinoma, Stage III Liver Cancer, Stage IV Liver Cancer","enrollment":88},{"nctId":"NCT02997228","phase":"PHASE3","title":"Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-19","conditions":"Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7","enrollment":120},{"nctId":"NCT07291076","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-03-16","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":129},{"nctId":"NCT04981509","phase":"PHASE2","title":"Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-10","conditions":"Hereditary Leiomyomatosis and Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma","enrollment":65},{"nctId":"NCT05001880","phase":"PHASE2","title":"Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-22","conditions":"Peritoneal Malignant Mesothelioma","enrollment":66},{"nctId":"NCT05063552","phase":"PHASE2, PHASE3","title":"Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-13","conditions":"Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma","enrollment":430},{"nctId":"NCT04158258","phase":"","title":"A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-02-21","conditions":"Breast Cancer","enrollment":2907},{"nctId":"NCT07059494","phase":"PHASE4","title":"Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2026-06","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT06133062","phase":"PHASE2","title":"Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2023-11-16","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":45},{"nctId":"NCT04102098","phase":"PHASE3","title":"A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2019-12-31","conditions":"Carcinoma, Hepatocellular","enrollment":668},{"nctId":"NCT05359861","phase":"PHASE2","title":"Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Coherus Oncology, Inc.","startDate":"2022-04-12","conditions":"Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT07010497","phase":"PHASE2","title":"A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2026-03-16","conditions":"Carcinoma, Hepatocellular","enrollment":33},{"nctId":"NCT05528952","phase":"PHASE2","title":"Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2022-09-27","conditions":"Hepatocellular Carcinoma","enrollment":105},{"nctId":"NCT03424005","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":"Metastatic Breast Cancer","enrollment":792},{"nctId":"NCT05468359","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-11-07","conditions":"Refractory Solid Tumor, Hepatocellular Carcinoma, Malignant Solid Tumor","enrollment":64},{"nctId":"NCT05862285","phase":"PHASE3","title":"A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-06-01","conditions":"Cancer","enrollment":100},{"nctId":"NCT07193316","phase":"","title":"Safety and Efficacy of Atezolizumab-Bevacizumab Versus Tyrosin Kinase Inhibitors in Patients With Liver Cirrhosis","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2023-07-27","conditions":"Hepatocellular Carcinoma, Liver Cirrhosis","enrollment":38},{"nctId":"NCT07381634","phase":"PHASE2","title":"The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2026-03-20","conditions":"Hepatocellular Carcinoma (HCC), IrAE","enrollment":134},{"nctId":"NCT03074513","phase":"PHASE2","title":"Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-03-03","conditions":"Appendix Adenocarcinoma, Human Papillomavirus-Related Anal Squamous Cell Carcinoma, Human Papillomavirus-Related Cervical Squamous Cell Carcinoma","enrollment":133},{"nctId":"NCT04931342","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-07","conditions":"Ovarian Cancer","enrollment":176},{"nctId":"NCT06254248","phase":"PHASE2","title":"Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-01-22","conditions":"Liver Transplant, Hepatocellular Carcinoma Recurrent, Systemic Treatment","enrollment":50},{"nctId":"NCT05665348","phase":"PHASE2, PHASE3","title":"Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2023-03-09","conditions":"HCC - Hepatocellular Carcinoma, Metastatic Cancer, Metastatic Tumor","enrollment":229},{"nctId":"NCT03178552","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-09-22","conditions":"Non-Small Cell Lung Cancer","enrollment":1000},{"nctId":"NCT06096779","phase":"PHASE2","title":"A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2024-07-15","conditions":"Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT04721132","phase":"PHASE2","title":"Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-02-10","conditions":"Resectable Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8, Stage IA Hepatocellular Carcinoma AJCC v8","enrollment":16},{"nctId":"NCT04563338","phase":"PHASE2","title":"An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2021-06-04","conditions":"Hepatocellular Carcinoma, Non-small Cell Lung Cancer Metastatic, Liver Metastases","enrollment":36},{"nctId":"NCT06823375","phase":"PHASE2","title":"SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2025-07-10","conditions":"HCC","enrollment":40},{"nctId":"NCT04929223","phase":"PHASE1","title":"A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-22","conditions":"Metastatic Colorectal Cancer","enrollment":542},{"nctId":"NCT05441475","phase":"PHASE2","title":"A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients","status":"ENROLLING_BY_INVITATION","sponsor":"Abbisko Therapeutics Co, Ltd","startDate":"2021-12-30","conditions":"Hepatocellular Carcinoma","enrollment":118},{"nctId":"NCT03942328","phase":"PHASE1, PHASE2","title":"Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2019-09-19","conditions":"Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8","enrollment":85},{"nctId":"NCT05488522","phase":"PHASE1","title":"SBRT With Atezo/Bev for HCC","status":"RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2022-09-01","conditions":"Hepatocellular Carcinoma","enrollment":18},{"nctId":"NCT05096715","phase":"PHASE1","title":"Atezolizumab+Bevacizumab+SBRT in Unresectable HCC","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2022-08-23","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":20},{"nctId":"NCT04770896","phase":"PHASE3","title":"A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-04-26","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":557},{"nctId":"NCT07263438","phase":"PHASE2","title":"Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2025-11-03","conditions":"Glioblastoma, Recurrence Tumor","enrollment":59},{"nctId":"NCT04449874","phase":"PHASE1","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2020-07-29","conditions":"Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors","enrollment":498},{"nctId":"NCT05546879","phase":"PHASE1","title":"Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC","status":"SUSPENDED","sponsor":"University Hospital, Grenoble","startDate":"2023-03-15","conditions":"Hepatocellular Carcinoma","enrollment":43},{"nctId":"NCT03896074","phase":"PHASE2","title":"Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Ricerca Traslazionale","startDate":"2020-03-02","conditions":"Non-small-cell Lung Cancer Patients","enrollment":206},{"nctId":"NCT07365930","phase":"","title":"NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy","status":"RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2025-12-17","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":350},{"nctId":"NCT06771622","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"FBD Biologics Limited","startDate":"2025-03-13","conditions":"Solid Cancer","enrollment":500},{"nctId":"NCT05733611","phase":"PHASE2","title":"RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC","status":"TERMINATED","sponsor":"Replimune Inc.","startDate":"2023-06-29","conditions":"Refractory Metastatic Colorectal Cancer, pMMR, MSS","enrollment":5},{"nctId":"NCT04712643","phase":"PHASE3","title":"A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-03-12","conditions":"Hepatocellular Carcinoma","enrollment":342},{"nctId":"NCT03768063","phase":"PHASE3","title":"A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2019-02-28","conditions":"Cancer","enrollment":1000},{"nctId":"NCT06739252","phase":"PHASE2","title":"Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA","status":"TERMINATED","sponsor":"Peking University","startDate":"2024-12-31","conditions":"Intrahepatic Cholangiocarcinoma (Icc), Perihilar Cholangiocarcinoma","enrollment":1},{"nctId":"NCT04958811","phase":"PHASE2","title":"Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Georgetown University","startDate":"2021-12-21","conditions":"Non-squamous Non-small-cell Lung Cancer","enrollment":29},{"nctId":"NCT05249426","phase":"PHASE1","title":"A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2022-04-12","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":48},{"nctId":"NCT07351513","phase":"PHASE2","title":"A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Eastern Hepatobiliary Surgery Hospital","startDate":"2026-01-30","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":94},{"nctId":"NCT07166406","phase":"PHASE3","title":"Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2025-10-07","conditions":"Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8","enrollment":252},{"nctId":"NCT04649489","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jia Fan","startDate":"2021-04-19","conditions":"Venous Thrombosis","enrollment":501},{"nctId":"NCT06439485","phase":"PHASE1, PHASE2","title":"Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-11-19","conditions":"Advanced Cholangiocarcinoma, FGFR2 Fusion","enrollment":25},{"nctId":"NCT03148418","phase":"PHASE3","title":"A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-09-20","conditions":"Cancer","enrollment":382},{"nctId":"NCT03181100","phase":"PHASE2","title":"Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-07-27","conditions":"Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8","enrollment":50},{"nctId":"NCT06921785","phase":"PHASE3","title":"Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-05-06","conditions":"Hepatocellular Carcinoma","enrollment":1220},{"nctId":"NCT05112965","phase":"PHASE3","title":"An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-12-01","conditions":"Neoplasms","enrollment":49},{"nctId":"NCT07317414","phase":"PHASE2","title":"β-alanine in the Treatment of Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-12-24","conditions":"Hepatocellular Carcinoma","enrollment":158},{"nctId":"NCT05904886","phase":"PHASE3","title":"A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-09-14","conditions":"Hepatocellular Carcinoma","enrollment":687},{"nctId":"NCT07293468","phase":"PHASE2, PHASE3","title":"Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)","status":"RECRUITING","sponsor":"Tuen Mun Hospital","startDate":"2024-04-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":106},{"nctId":"NCT05044676","phase":"","title":"Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-09-08","conditions":"Hepatocellular Carcinoma","enrollment":4},{"nctId":"NCT06551142","phase":"PHASE1","title":"A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-09-30","conditions":"Neoplasms","enrollment":590},{"nctId":"NCT06478693","phase":"PHASE1","title":"A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC","status":"RECRUITING","sponsor":"Myeloid Therapeutics","startDate":"2024-07-01","conditions":"Hepatocellular Carcinoma","enrollment":70},{"nctId":"NCT06908993","phase":"PHASE3","title":"Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated","status":"RECRUITING","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2025-12-09","conditions":"Advanced Non Small Cell Lung Cancer, MET Exon 14 Mutation","enrollment":133},{"nctId":"NCT07285850","phase":"PHASE2, PHASE3","title":"The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD","status":"RECRUITING","sponsor":"Eastern Hepatobiliary Surgery Hospital","startDate":"2025-10-20","conditions":"HCC - Hepatocellular Carcinoma","enrollment":20},{"nctId":"NCT05263830","phase":"","title":"Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-09-08","conditions":"Hepatocellular Carcinoma","enrollment":240},{"nctId":"NCT05733598","phase":"PHASE2","title":"Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC","status":"RECRUITING","sponsor":"Replimune Inc.","startDate":"2024-08-01","conditions":"Hepatocellular Carcinoma, Biliary Tract Cancer","enrollment":60},{"nctId":"NCT07281664","phase":"NA","title":"Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2026-01-01","conditions":"Hepatocellular Carcinoma, Transarterial Chemoembolization","enrollment":30},{"nctId":"NCT03337698","phase":"PHASE1, PHASE2","title":"A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-12-27","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":314},{"nctId":"NCT04862949","phase":"","title":"Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC","status":"COMPLETED","sponsor":"CHA University","startDate":"2021-05-01","conditions":"Advanced Hepatocellular Carcinoma","enrollment":131},{"nctId":"NCT05908786","phase":"PHASE1, PHASE2","title":"A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2023-12-05","conditions":"Carcinoma, Hepatocellular","enrollment":62},{"nctId":"NCT07276100","phase":"PHASE2","title":"Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab","status":"RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2026-01-01","conditions":"Hepato Cellular Carcinoma (HCC)","enrollment":15},{"nctId":"NCT07272265","phase":"NA","title":"The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2020-10-28","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":300},{"nctId":"NCT06733038","phase":"PHASE3","title":"FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2024-11-15","conditions":"Colorectal Cancer","enrollment":238},{"nctId":"NCT03836066","phase":"PHASE2","title":"Atezolizumab Plus Bevacizumab in First Line NSCLC Patients","status":"COMPLETED","sponsor":"Fundación GECP","startDate":"2019-05-15","conditions":"Non Small Cell Lung Cancer","enrollment":41},{"nctId":"NCT07157969","phase":"PHASE2","title":"ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-02-19","conditions":"HCC - Hepatocellular Carcinoma","enrollment":300},{"nctId":"NCT05180006","phase":"PHASE2","title":"Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy","status":"TERMINATED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2022-02-24","conditions":"Breast Cancer","enrollment":33},{"nctId":"NCT05287464","phase":"","title":"International Multicentric Study ARON-1","status":"RECRUITING","sponsor":"Hospital of Macerata","startDate":"2022-03-10","conditions":"Metastatic Renal Cell Carcinoma (mRCC)","enrollment":1220},{"nctId":"NCT07239245","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-11-12","conditions":"Resectable Hepatocellular Carcinoma With High Risk of Recurrence","enrollment":30},{"nctId":"NCT07246668","phase":"PHASE2","title":"A Phase II Single-Arm Clinical Study to Evaluate the Efficacy and Safety of Carbon Ion Radiotherapy With Atezolizumab and Bevacizumab Combination Therapy in Patients With Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2025-03-10","conditions":"Hepatocellular Carcinoma, Liver Neoplasms, Carcinoma","enrollment":52},{"nctId":"NCT03193190","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-07-05","conditions":"Pancreatic Adenocarcinoma","enrollment":341},{"nctId":"NCT03498521","phase":"PHASE2","title":"A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-07-10","conditions":"Cancer of Unknown Primary Site","enrollment":529},{"nctId":"NCT05781308","phase":"PHASE2","title":"Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2023-04-26","conditions":"Non Small Cell Lung Cancer","enrollment":156},{"nctId":"NCT05751343","phase":"PHASE2","title":"Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-03-09","conditions":"Hepatocellular Carcinoma","enrollment":55},{"nctId":"NCT05588388","phase":"PHASE2","title":"Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases","status":"RECRUITING","sponsor":"Kamya Sankar","startDate":"2024-08-11","conditions":"Extensive-stage Small-cell Lung Cancer, Liver Metastases","enrollment":39},{"nctId":"NCT06117891","phase":"","title":"An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery","status":"RECRUITING","sponsor":"Bayer","startDate":"2023-11-27","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":300},{"nctId":"NCT03468426","phase":"PHASE1","title":"A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2018-07-05","conditions":"Non-squamous, Non-Small-Cell Lung Cancer, Neoplasms","enrollment":252},{"nctId":"NCT03280563","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-12-22","conditions":"Breast Neoplasms","enrollment":144},{"nctId":"NCT03175432","phase":"PHASE2","title":"Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-06-15","conditions":"BRAF V600 Wild Type, Clinical Stage IV Cutaneous Melanoma AJCC v8, Intracranial Melanoma","enrollment":29},{"nctId":"NCT03526432","phase":"PHASE2","title":"Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oklahoma","startDate":"2018-08-08","conditions":"Endometrial Cancer","enrollment":110},{"nctId":"NCT05440708","phase":"PHASE1, PHASE2","title":"A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Tvardi Therapeutics, Incorporated","startDate":"2023-03-23","conditions":"Hepatocellular Carcinoma","enrollment":178},{"nctId":"NCT04185883","phase":"PHASE1","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2019-12-17","conditions":"Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation","enrollment":610},{"nctId":"NCT05620771","phase":"PHASE2","title":"Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk","status":"SUSPENDED","sponsor":"Northwestern University","startDate":"2022-11-30","conditions":"Hepatocellular Carcinoma","enrollment":84},{"nctId":"NCT03520686","phase":"PHASE3","title":"Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-18","conditions":"Non Small Cell Lung Cancer","enrollment":1538},{"nctId":"NCT03141684","phase":"PHASE2","title":"Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-25","conditions":"Metastatic Alveolar Soft Part Sarcoma, Unresectable Alveolar Soft Part Sarcoma","enrollment":63},{"nctId":"NCT06789757","phase":"PHASE2","title":"The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)","status":"RECRUITING","sponsor":"Inova Health Care Services","startDate":"2025-02-25","conditions":"Hepatocellular Carcinoma","enrollment":19},{"nctId":"NCT05377034","phase":"PHASE2","title":"Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients","status":"RECRUITING","sponsor":"National Cancer Centre, Singapore","startDate":"2022-10-26","conditions":"Locally Advanced Hepatocellular Carcinoma","enrollment":100},{"nctId":"NCT06784947","phase":"PHASE2","title":"Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2025-03-25","conditions":"Microsatellite Stable (MSS) Colorectal Cancer (CRC), Metastatic Colorectal Cancer (CRC), Colorectal Cancer Stage IV","enrollment":13},{"nctId":"NCT07204327","phase":"","title":"Atezolizumab Plus Bevacizumab Combined With Locoregional Therapies in Unresectable Hepatocellular Carcinoma (ISMIO-001)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zhongda Hospital","startDate":"2020-10-28","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":1136},{"nctId":"NCT02982694","phase":"PHASE2","title":"Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer","status":"TERMINATED","sponsor":"Vall d'Hebron Institute of Oncology","startDate":"2017-11-24","conditions":"MSI, ColoRectal Cancer, Chemotherapy","enrollment":46},{"nctId":"NCT04857684","phase":"EARLY_PHASE1","title":"SBRT + Atezolizumab + Bevacizumab in Resectable HCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2021-06-18","conditions":"Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma","enrollment":20},{"nctId":"NCT04727307","phase":"PHASE2","title":"Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2021-02-23","conditions":"Hepatocellular Carcinoma","enrollment":202}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":925,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Avastin plus Tecentriq"],"phase":"phase_2","status":"active","brandName":"Bevacizumab plus Atezolizumab","genericName":"Bevacizumab plus Atezolizumab","companyName":"Ze-yang Ding, MD","companyId":"ze-yang-ding-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), while atezolizumab is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1), thereby enhancing anti-tumor immune response. Used for Non-small cell lung cancer, metastatic or recurrent, Renal cell carcinoma, metastatic, Urothelial carcinoma, locally advanced or metastatic.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}